LEXINGTON, Mass.--(BUSINESS WIRE)--Kevin Hrusovsky, founder of Powering Precision Health and chairman and CEO of Quanterix, will take the stage at MedCity CONVERGE to discuss the power of noninvasive testing with the use of predictive biomarkers to diagnose cancers in its earliest stages. The session will take place on July 11 at 5 p.m. EDT.
Hrusovsky, acclaimed thought leader and precision health visionary, joins top health care leaders providing actionable insight on where oncology innovation is heading. Hrusovsky and fellow panelist Bonnie Anderson, chairman and CEO of Veracyte, will examine emerging technologies and the evolution of the health care landscape that will shape cancer diagnostics in the future.
Cancer is among the leading causes of death worldwide, with 1.7 million people in the U.S. estimated to be diagnosed with cancer by the end of 2018, according to the National Cancer Institute. Hrusovsky, EY Entrepreneur of the Year finalist in the New England region, will describe the technology transforming the way we diagnose and treat disease, which has the potential to radically shift our health care model.
“We need to change our thinking about cancer detection and treatment beyond imaging and radiation,” said Hrusovsky. “We now have the technological advancements to detect biomarkers, or proteins in the blood that indicate disease, earlier than ever before. This technology will allow us to catch disease years before patients ever feel symptoms – when disease is most curable and cost-effective to treat. A non-invasive blood test to assess individuals’ biomarkers is the cancer breakthrough we need to reduce unnecessary tests and radiation exposure.”
In the session, Hrusovsky will point to third-party, peer-reviewed biomarker research that shows promise for early detection, and discuss what it means for providers, pharmaceutical companies and patients.
MedCity CONVERGE is a two-day executive summit that gathers innovative thought leaders ranging from technology disruptors, payers and providers to life science companies and venture capitalists to discuss how AI, big data and precision health are changing the game in cancer. The conference takes place on July 11-12, 2018 in Philadelphia. To register or view the agenda, visit: https://events.medcitynews.com/converge/
About Powering Precision Health
Powering Precision Health is the nation's leading summit dedicated to bringing the world's top physicians, scientists, innovators and patient advocates together to collaborate on the latest research on new biomarkers that are revolutionizing medicine. Founded by Kevin Hrusovsky, the acclaimed thought leader and visionary in life sciences and personalized health, PPH is an executive think tank of researchers and clinicians working together to transform health care. Addressing key therapeutic areas, including neurology, cardiology, oncology and infectious disease, PPH unveils groundbreaking approaches for the prevention, early detection and diagnosis, and personalized treatment of disease. Join the movement on social media using #PPHSUMMIT on Twitter @KevinHrusovsky and @PPHSUMMIT, and LinkedIn.
